Table 1.
Baseline Characteristics by NPS Class
| Variable | All Sample | class 1 | class 2 | class 3 | class 4 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | 9,797 | 4,721 | 3,562 | 1,250 | 264 | |||||
| Age, mean, SD | 73.7 | 9.2 | 74.3 | 9.0 | 72.9 | 9.4 | 74.1 | 9.0 | 74.1 | 9.3 |
| Male, N, % | 4,634 | 47.3 | 2,294 | 48.6 | 1,596 | 44.8 | 636 | 50.9 | 104 | 39.4 |
| Non-Hispanic White, N, % | 7,622 | 77.8 | 3,777 | 80.0 | 2,793 | 78.4 | 901 | 72.1 | 153 | 58.0 |
| Years of schooling, mean, SD | 14.9 | 3.6 | 15.2 | 3.4 | 14.8 | 3.6 | 14.3 | 3.8 | 13.3 | 4.0 |
| Follow up years, mean, SD | 4.0 | 2.2 | 4.1 | 2.3 | 4.0 | 2.2 | 3.8 | 2.1 | 3.3 | 1.7 |
| Referred by professionals, N, % | 5,780 | 59.0 | 2,677 | 56.7 | 2,194 | 61.6 | 740 | 59.2 | 167 | 63.3 |
| Diabetes, N, % | 1,215 | 12.4 | 533 | 11.3 | 452 | 12.7 | 188 | 15.0 | 43 | 16.3 |
| Hypertension, N, % | 5,251 | 53.6 | 2,464 | 52.2 | 1,909 | 53.6 | 721 | 57.7 | 159 | 60.1 |
| Hypercholesterolemia, N, % | 5,173 | 52.8 | 2,483 | 52.6 | 1,888 | 53.0 | 678 | 54.2 | 124 | 46.8 |
| Apolipoprotein (ApoE) ε4 allele, N, % | ||||||||||
| None | 5,055 | 51.6 | 2,521 | 53.4 | 1,745 | 49.0 | 645 | 51.6 | 143 | 54.1 |
| Homozygote | 3,625 | 37.0 | 1,690 | 35.8 | 1,371 | 38.5 | 468 | 37.4 | 96 | 36.4 |
| Heterozygote | 1,117 | 11.4 | 510 | 10.8 | 445 | 12.5 | 138 | 11.0 | 25 | 9.5 |
| Mini-Mental State Examination (MMSE), mean, SD | 2,234 | 22.8 | 1,124 | 23.8 | 794 | 22.3 | 269 | 21.5 | 48 | 18.0 |
| Functional Assessment Questionnaire (FAQ), mean, SD | 11.1 | 8.6 | 8.4 | 7.9 | 12.7 | 8.2 | 15.0 | 8.6 | 20.2 | 7.9 |
| Neuropsychiatric Inventory Questionnaire (NPI-Q), mean, SD | 4.0 | 4.1 | 2.3 | 3.0 | 4.4 | 3.7 | 9.4 | 5.2 | 7.9 | 4.9 |
| Total number of medications, mean, SD | 6.3 | 3.9 | 6.2 | 3.9 | 6.5 | 4.0 | 6.5 | 3.9 | 6.1 | 3.8 |
| Antihypertensive or blood pressure medications, N, % | 5,251 | 53.6 | 2,526 | 53.5 | 1,899 | 53.3 | 688 | 55.0 | 141 | 53.4 |
| Lipid lowering med | 4,477 | 45.7 | 2,167 | 45.9 | 1,642 | 46.1 | 568 | 45.4 | 101 | 38.3 |
| Nonsteroidal anti-inflammatory drugs | 3,674 | 37.5 | 1,898 | 40.2 | 1,279 | 35.9 | 414 | 33.1 | 81 | 30.7 |
| Anticoagulant or antiplatelet | 3,615 | 36.9 | 1,846 | 39.1 | 1,272 | 35.7 | 416 | 33.3 | 83 | 31.4 |
| Antidepressant | 3,468 | 35.4 | 1,020 | 21.6 | 1,749 | 49.1 | 574 | 45.9 | 122 | 46.2 |
| Beta-adrenergic blocking agent | 1,920 | 19.6 | 944 | 20.0 | 687 | 19.3 | 248 | 19.8 | 48 | 18.2 |
| Angiotensin convert enzyme inh. | 1,773 | 18.1 | 817 | 17.3 | 666 | 18.7 | 240 | 19.2 | 48 | 18.2 |
| Calcium channel blocking agent | 1,411 | 14.4 | 670 | 14.2 | 513 | 14.4 | 194 | 15.5 | 35 | 13.3 |
| Diuretic | 1,313 | 13.4 | 614 | 13.0 | 477 | 13.4 | 181 | 14.5 | 37 | 14.0 |
| Angiotensin II inhibitor | 1,038 | 10.6 | 519 | 11.0 | 363 | 10.2 | 131 | 10.5 | 26 | 9.8 |
| Anxiolytic, sedative or hypnotic | 1,078 | 11.0 | 482 | 10.2 | 403 | 11.3 | 159 | 12.7 | 35 | 13.3 |
| Diabetes meds | 950 | 9.7 | 411 | 8.7 | 349 | 9.8 | 150 | 12.0 | 37 | 14.0 |
| Antiadrenergic agent | 843 | 8.6 | 406 | 8.6 | 285 | 8.0 | 125 | 10.0 | 22 | 8.3 |
| Antihypertensive combo therapy | 402 | 4.1 | 179 | 3.8 | 153 | 4.3 | 54 | 4.3 | 10 | 3.8 |
| Estrogen hormone therapy | 225 | 2.3 | 109 | 2.3 | 96 | 2.7 | 23 | 1.8 | 5 | 1.9 |
| Antiparkinsonian agent | 196 | 2.0 | 80 | 1.7 | 82 | 2.3 | 24 | 1.9 | 6 | 2.3 |
| Vasodilator | 167 | 1.7 | 80 | 1.7 | 61 | 1.7 | 26 | 2.1 | 2 | 0.8 |
| Antipsychotic agent | 343 | 3.5 | 47 | 1.0 | 121 | 3.4 | 110 | 8.8 | 59 | 22.3 |
| Estrogen + progestin therapy | 29 | 0.3 | 9 | 0.2 | 14 | 0.4 | 1 | 0.1 | 0 | 0.0 |
Notes: Between class differences statistically significant at p<0.001 for all variables except for hypercholesterolemia (p=0.172)